Journal
NANOMATERIALS
Volume 7, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/nano7040077
Keywords
siRNA; nanoparticles; delivery systems; cancer therapy; tumor; RNAi; gene delivery; targeted delivery
Categories
Funding
- US National Institutes of Health, National Cancer Institute (NIH/NCI) [R21CA179652]
- Wayne State University Start-up funding
Ask authors/readers for more resources
siRNA is a promising therapeutic solution to address gene overexpression or mutations as a post-transcriptional gene regulation process for several pathological conditions such as viral infections, cancer, genetic disorders, and autoimmune disorders like arthritis. This therapeutic method is currently being actively pursued in cancer therapy because siRNA has been found to suppress the oncogenes and address mutations in tumor suppressor genes and elucidate the key molecules in cellular pathways in cancer. It is also effective in personalized gene therapy for several diseases due to its specificity, adaptability, and broad targeting capability. However, naked siRNA is unstable in the bloodstream and cannot efficiently cross cell membranes besides being immunogenic. Therefore, careful design of the delivery systems is essential to fully utilize the potential of this therapeutic solution. This review presents a comprehensive update on the challenges of siRNA delivery and the current strategies used to develop nanoparticulate delivery systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available